NCT07312955

Solifenacin Plus Tadalafil vs Solifenacin Alone for Overactive Bladder in Females

Efficacy of Combination of Solifenacin and Tadalafil Versus Solifenacin Alone in Treatment of Overactive Bladder in Females

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Ain Shams University · Academic / Other
• Sex: Female
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Overactive bladder (OAB) is characterized by urinary urgency with or without urge urinary incontinence, usually with frequency and nocturia, in the absence of urinary tract infection or other obvious pathology. Antimuscarinic agents such as solifenacin are commonly used but may provide incomplete symptom control. Tadalafil (a Phosphodiesterase type 5 inhibitorsinhibitor) has been reported to improve lower urinary tract symptoms and may offer additional benefit in overactive bladder. This randomized controlled trial evaluates the efficacy and tolerability of solifenacin 5 mg plus tadalafil 5 mg versus solifenacin 5 mg alone in females with overactive bladder using the Overactive Bladder Symptom Score (OABSS).

Conditions

• Overactive Bladder

Interventions

Type	Name	Description
DRUG	Solifenacin	Solifenacin 5 mg oral tablet, once daily for 3 months.
DRUG	Tadalafil	Tadalafil 5 mg oral tablet, once daily for 3 months.

Timeline

• Start date: 2025-05-15
• Primary completion: 2025-11-15
• Completion: 2025-11-15
• First posted: 2025-12-31
• Last updated: 2025-12-31

Locations

1 site across 1 country: Egypt